Abstract:Introduction: It is well established that toll-like receptors (TLRs) expressed in APCs, especially in dendritic cells (DCs), play important role in many immune responses. All TLR signals except TLR3 depend either entirely or in part on the MyD88 (myeloid differentiation protein 88). However, there is no direct evidence that MyD88 is the trigger and controller for transplantation rejection. In this study, we investigate the essential role of MyD88 in DCs in transplant rejection response by a MyD88 specific inhibitor using a HY-mismatched skin allograft model in mice. Methods: Minor antigen-mismatched (HY-mismatched) skin allograft model (BALB/c ♂ → BALB/c ♀) using MyD88-knockout mice was employed in this study. Wild-type BALB/c immature BMDCs were cocultured with or without ST2825, a novel inhibitor of MyD88, in vitro for 12 hours. DCs treated with or without ST2825 were then transfused into recipients (2×107/mouse) at the time of skin transplantation. Wild-type BALB/c BMDCs were stimulated by TLR agonists in the presence of ST2825 or not for 12 hours in vitro. Costimulatory molecular CD80 were analyzed by flow cytometry and NF-κB activity in nuclei was detected by western blot. Wild-type C57BL/6 T cells stained with CFSE were cocultured with BALB/c DCs for 3 days in the presence of ST2825 or not. CD3+/CFSE+ cells were analyzed by flow cytometry. Results: ST2825 inhibited the upregulation of CD80 and reduced NF-κB activity of DCs upon the stimulation of TLR agonists in vitro. ST2825 dose-dependently inhibited T cell proliferation in mixed lymphocyte culture. The rejection of HY-mismatched skin allografts in MyD88 KO mice could not occur and an immune tolerance was established. The group infused with DCs without ST2825 treatment reversed the tolerance in H-Y mismatched skin transplant in MyD88 KO mice, but the group with DCs treated with ST2825 does not, as shown in Fig 1.Figure: [Rejection depends on the presence of MyD88 in DCs]Conclusion: This study provides profound evidence that the MyD88 in DCs plays important role in transplant alloresponses. MyD88 inhibitor ST2825 leads to effective blocking to TLR signaling in DCs.

AA28-67 domain within MyD88 suppresses c-myc activity and expression to regulate differentiation and function of dendritic cells.

Aa155-171 Motif Deletion of MyD88 Attenuates Expression of Co-stimulatory Molecules and Cytokines in Immune Associated-cells

Transcription factor E2F1 suppresses dendritic cell maturation.

Transcription factor E2F1 suppresses dendritic cell maturation. (167.3)

MyD 88 Intrinsically Regulates CD 4 T-Cell Responses

JAK/STAT signaling pathway in the process of differentiation and maturation of Dendritic calls

A Robust Proof For The Essential Role Of Myd88 In Dcs In Transplant Responses

The MYCL and MXD1 transcription factors regulate the fitness of murine dendritic cells

MyD88 in Myofibroblasts Enhances Colitis-Associated Tumorigenesis Via Promoting Macrophage M2 Polarization

Blockade of Myd88 Signaling by Novel MyD88 Inhibitor Prevents Colitis-associated Colorectal Cancer From Development by Impairing Myeloid-Derived Suppressor Cells

Dendritic cells play an essential role in transplantation responses via myeloid differentiation factor 88 signaling.

CCDC134 Facilitates T Cell Activation Through the Regulation of Early T Cell Receptor Signaling.

Abstract 4966: MyD88 in Myofibroblasts Enhances Colitis-Associated Tumorigenesis Via Promoting Macrophage M2 Polarization in Mice

MyD88 Shapes Vaccine Immunity by Extrinsically Regulating Survival of CD4+ T Cells during the Contraction Phase

MicroRNA-148/152 Impair Innate Response and Antigen Presentation of TLR-triggered Dendritic Cells by Targeting CaMKIIα.

Conformational Dynamics of Cancer-Associated MyD88-TIR Domain Mutant L252P (L265P) Allosterically Tilts the Landscape Toward Homo-Dimerization.

Dendritic Cell MST1 Inhibits Th17 Differentiation

MyD88 NEDDylation Negatively Regulates MyD88-dependent NF-κB Signaling Through Antagonizing Its Ubiquitination.

E2F1 Suppreses DC Maturation (88.22)

MYD88 L265P elicits mutation-specific ubiquitination to drive NF-κB activation and lymphomagenesis

Signaling Via the Kinase P38α Programs Dendritic Cells to Drive TH17 Differentiation and Autoimmune Inflammation.